Our Publications
Published
GPR68 limits the severity of chemical-induced oral epithelial dysplasia
Shore, D., Griggs, N., Graffeo, V., Amin, A. R., Zha, X.-ming, Xu, Y., & McAleer, J. P. (2023). GPR68 limits the severity of chemical-induced oral epithelial dysplasia. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-27546-y
Published
Inhibition of triple negative breast cancer-associated inflammation and progression by N- acylethanolamine acid amide hydrolase (NAAA)
Benchama, O., Malamas, M. S., Praveen, K., Ethier, E. C., Williams, M. K., Makriyannis, A., & Avraham, H. K. (2022). Inhibition of triple negative breast cancer-associated inflammation and progression by n- acylethanolamine acid amide hydrolase (NAAA). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-26564-6
Published
Redox-responsive polyurethane-polyurea nanoparticles targeting to aortic endothelium and atherosclerosis
Zhou, Y., Hou, D., Marigo, C. C., Bonelli, J., Rocas, P., Cheng, F., Yang, X., Rocas, J., Hamberg, N. M., & Han, J. (2022). Redox-responsive polyurethane-polyurea nanoparticles targeting to aortic endothelium and atherosclerosis. IScience, 25(11), 105390. https://doi.org/10.1016/j.isci.2022.105390
Published
mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
Huang, Z., You, X., Chen, L., Du, Y., Brodeur, K., Jee, H., Wang, Q., Linder, G., Darbousset, R., Cunin, P., Chang, M. H., Wactor, A., Wauford, B. M., Todd, M. J., Wei, K., Li, Y., Levescot, A., Iwakura, Y., Pascual, V., … Lee, P. Y. (2022). MTORC1 links pathology in experimental models of still’s disease and macrophage activation syndrome. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34480-6
Published
Tissue-specific modifier alleles determine Mertk loss-of-function traits
Akalu, Y. T., Mercau, M. E., Ansems, M., Hughes, L. D., Nevin, J., Alberto, E. J., Liu, X. N., He, L.-Z., Alvarado, D., Keler, T., Kong, Y., Philbrick, W. M., Bosenberg, M., Finnemann, S. C., Iavarone, A., Lasorella, A., Rothlin, C. V., & Ghosh, S. (2022). Tissue-specific modifier alleles determine mertk loss-of-function traits. ELife, 11. https://doi.org/10.7554/elife.80530
Published
RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3KmTOR inhibition
Fang, L., Ford-Roshon, D., Russo, M., O’Brien, C., Xiong, X., Gurjao, C., Grandclaudon, M., Raghavan, S., Corsello, S. M., Carr, S. A., Udeshi, N. D., Berstler, J., Sicinska, E., Ng, K., & Giannakis, M. (2022). RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mtor inhibition. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30794-7
Published
Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response
Li, Wanjin, et al. “Nuclear Ripk1 Promotes Chromatin Remodeling to Mediate Inflammatory Response.” Cell Research, 2022, https://doi.org/10.1038/s41422-022-00673-3.
Published
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma
Wu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.J., Yin, X. and Ferrone, C.R., 2022. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinomaCombination Treatment in FGFR2-Fusion Cholangiocarcinoma. Cancer Discovery.
Published
Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor
Wu, M.J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.Y., Kessler, E., Olander, K.E., Adil, R., Pankaj, A. and Tummala, K.S., 2021. Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer discovery.
Published
A BDNF-TrkB autocrine loop enhances senescent cell viability
Anerillas, C., Herman, A. B., Munk, R., Garrido, A., Lam, K.-W. G., Payea, M. J., Rossi, M., Tsitsipatis, D., Martindale, J. L., Piao, Y., Mazan-Mamczarz, K., Fan, J., Cui, C.-Y., De, S., Abdelmohsen, K., de Cabo, R., & Gorospe, M. (2022). A BDNF-TrkB autocrine loop enhances senescent cell viability. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-33709-8
Published
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K.H., Cao, S., Chouitar, J., Wu, J. and Peng, D., 2021. Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer research, 81(20), pp.5311-5324.
Published
Mobocertinib (TAK-788) A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non−Small Cell Lung Cancer
Gonzalvez, F., Vincent, S., Baker, T.E., Gould, A.E., Li, S., Wardwell, S.D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.S. and Hu, Y., 2021. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non–small cell lung cancer. Cancer discovery, 11(7), pp.1672-1687.